
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

Dated June 30, 2016

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant's Name)

**#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272**

(Address and telephone number of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [] Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): []

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [] No []

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 30, 2016.

Aurinia Pharmaceuticals Inc.

By: /s/ Dennis Bourgeault

Name: Dennis Bourgeault

Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
<u>99.1</u>	<u>Material Change Report dated June 15, 2016</u>

**FORM 51-102F3
Material Change Report**

Item 1 Name and Address of Company

Aurinia Pharmaceuticals Inc. (the "**Company**") #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8

Item 2 Date of Material Change

June 15, 2016

Item 3 News Release

A news release was issued and disseminated by the Company through Business Wire on June 15, 2016.

Item 4 Summary of Material Change

The Company announced, subject to regulatory approval, a US\$7,080,000 private placement (the "**Offering**").

Item 5 Full Description of Material Change

On June 15, 2016, the Company announced the Offering. The Company intends to use the net proceeds from the Offering for general corporate purposes, including financing research and development, clinical expenses, and corporate costs.

Under the terms of the Offering, the Company will issue 3,000,000 units (the "**Units**") at a subscription price per Unit of US\$2.36, each Unit consisting of one common share ("**Common Share**") and 0.35 of one common share purchase warrant (each full warrant, a "**Warrant**"), with each Warrant exercisable for a period of 24 months from the date of closing of the Offering at an exercise price of US\$2.77.

Canaccord Genuity Inc. acted as placement agent for the Offering.

Item 5.2 Disclosure of Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

No significant facts remain confidential in, and no information has been omitted from, this report.

Item 8 Executive Officer

For further information, please contact:

Mr. Michael R. Martin, Chief Operating Officer
250-415-9713
mmartin@auriniapharma.com

Item 9 Date of Report

June 23, 2016
